NCT02487693Active, not recruitingPhase 2
Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma
Source: ClinicalTrials.gov · Last updated 23 Feb 2016
Brief summary (registry, in English)
The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 29 Jun 2015
- Start date
- 1 Jul 2015
- Primary completion date
- 30 Jun 2038
- Lead sponsor
- The First People's Hospital of Changzhou
- Diseases
- Ovarian cancer
- NCT number
- NCT02487693
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 1 Jul 2015 to the primary completion date, 30 Jun 2038
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- neoadjuvant chemotherapy applied;
- less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed;
Other illness
- history of previous malignancy.
Other
- medical records maintain incomplete data on treatment or follow-up;
Who the study is looking for
- patients diagnosed with FIGO stage II ovarian carcinoma;
- cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed;
- medical records maintain comprehensive data on treatment and follow-up;
- no history of previous malignancies.
Age in the registry: 30 years to 70 years · Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.